Literature DB >> 29652784

A Prospective, Randomized, Multicenter Study Comparing Silicated Calcium Phosphate versus BMP-2 Synthetic Bone Graft in Posterolateral Instrumented Lumbar Fusion for Degenerative Spinal Disorders.

Marc Coughlan1, Mark Davies2, Adriaan K Mostert3, Dharmin Nanda4, Paul C Willems5, Geoffrey Rosenberg6, Richard Ferch7.   

Abstract

STUDY
DESIGN: A prospective, Phase IV, multicenter, randomized study.
OBJECTIVE: The aim of this study was to compare vertebral fusion success rates following posterolateral fusion [(PLF)/posterolateral intertransverse fusion (PITF)] surgery. The surgical procedure combined posterior lumbar interbody fusion (PLIF) and PLF with internal fixation over one or two levels using silicated calcium phosphate (SiCaP) or bone morphogenetic protein (BMP)-2 as graft material in patients with a degenerative disorder of the lumbar spine. SUMMARY OF BACKGROUND DATA: Few controlled trials have evaluated the bone graft materials available to surgeons treating patients with spinal disorders, including degenerative disc disease, spondylolisthesis, and disc herniation.
METHODS: Following randomization, the surgical procedure consisting of PLIF and PLF with internal fixation over one or two levels was performed using SiCaP or BMP-2. No other osteoconductive/osteoinductive graft materials were permitted. Spinal fusion was assessed radiographically at ≤24 months. Clinical outcomes (pain on visual analog scale, Oswestry Disability Index, SF-36) and adverse events (AEs) were monitored.
RESULTS: One hundred three patients were enrolled. At 12 months, fusion was achieved in 25 of 35 (71.4%) of the SiCaP and 20 of 27 (74.1%) of the BMP-2 group, respectively (P = 1.000). At 24 months, the fusion rate was 78.6% and 84.8% for SiCaP and BMP-2, respectively (P = 0.5613). Clinical outcomes improved similarly in both groups over time. AEs were consistent with this surgical population.
CONCLUSION: SiCaP was safe and well tolerated in patients with degenerative spinal disorders requiring PLF and provided fusion rates similar to BMP-2. LEVEL OF EVIDENCE: 2.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29652784     DOI: 10.1097/BRS.0000000000002678

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  3 in total

Review 1.  Design and clinical application of injectable hydrogels for musculoskeletal therapy.

Authors:  Øystein Øvrebø; Giuseppe Perale; Jonathan P Wojciechowski; Cécile Echalier; Jonathan R T Jeffers; Molly M Stevens; Håvard J Haugen; Filippo Rossi
Journal:  Bioeng Transl Med       Date:  2022-03-15

2.  Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat degenerative spinal disease: a protocol of prospective, randomized controlled, assessor-blinded, open-label, multicenter trial.

Authors:  Jun-Young Choi; Hyun-Jin Park; Sang-Min Park; Chang-Nam Kang; Kwang-Sup Song
Journal:  J Orthop Surg Res       Date:  2022-08-31       Impact factor: 2.677

3.  Increasing Fusion Rate Between 1 and 2 Years After Instrumented Posterolateral Spinal Fusion and the Role of Bone Grafting.

Authors:  A Mechteld Lehr; F Cumhur Oner; Diyar Delawi; Rebecca K Stellato; Eric A Hoebink; Diederik H R Kempen; Job L C van Susante; René M Castelein; Moyo C Kruyt
Journal:  Spine (Phila Pa 1976)       Date:  2020-10-15       Impact factor: 3.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.